Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1581P - Impact of the COVID-19 pandemic on patients with head and neck cancer assisted in a public cancer center in Brazil

Date

16 Sep 2021

Session

ePoster Display

Topics

COVID-19 and Cancer

Tumour Site

Head and Neck Cancers

Presenters

Gilson Viana Veloso

Citation

Annals of Oncology (2021) 32 (suppl_5): S1129-S1163. 10.1016/annonc/annonc713

Authors

G.G. Viana Veloso1, A. Nogueira Rodrigues2

Author affiliations

  • 1 Oncology, Santa Casa de Misericórdia de Belo Horizonte, 30150-320 - Belo Horizonte/BR
  • 2 Oncology, Universidade Federal de Minas Gerais, 30130100 - Belo Horizonte/BR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1581P

Background

Since the beginning of the COVID-19 pandemic, over 400,000 Brazilians have died and its impact on other diseases is yet to be revealed. Due to contingency strategies, there was a significant reduction in screening programs and this will probably affect cancer treatment outcomes. There is no updated national data regarding the real impact on delaying diagnosis and cancer treatment in Brazil. Objective: To analyze whether the COVID-19 pandemic impacted delaying cancer treatment, yielding more advanced cases as analyzing patients’ clinical features before oncological treatment.

Methods

This is a retrospective cross-sectional study with patients assisted in a public cancer center in southeastern Brazil between 2019 and 2020 with a comparison of patients’ clinical features in both years. We analyzed all 207 patients with head and neck treated in 2019 and 2020 (85 and 122 patients, respectively) and stratified them by clinical stage (CS), tumor size, lymph node status (LNS), the occurrence of metastatic disease (MD), body mass index (BMI), need of enteral nutrition, age, performance status (PS) and the indication of exclusive palliative care. We performed comparisons between these groups using Student t-test and chi-square test with a significance level of 5%.

Results

Our results reported a statistically significant difference on tumor size (p 0,024); in 2019 50,6% of the tumors were classified as T4 in comparison with 66,4% in 2020. Data showed no statistically significant difference among groups regarding age (median of 56y in 2019 and 58,5y in 2020; p 0,056), BMI (47% had a BMI below 20 on each group, p 0,595), need of enteral nutritional (54,1% in 2019 and 59,8% in 2020, p 0,254), CS (75,3% had stage IV disease in 2019 and 81,1% in 2020 – p 0,486), LNS (42% were N2 in 2019 and 38,5% in 2020, p 0,243), MD (9,4% in 2019 and 13,9% in 2020, p 0,326), PS (59% had PS 1 in 2019 and 45% in 2020, p 0,061) and indication of exclusive palliative care (4,7% in 2019 and 10,7% in 2020, p 0,125).

Conclusions

The real impact of the COVID-19 pandemic in cancer treatment is yet to be discovered but so far, our results from 2020 patients indicated a tendency of advanced primary tumor size at the time of cancer diagnosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.